Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 3:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–22 of 22 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Multiple Myeloma
Interventions
Ixazomib, Placebo, Dexamethasone, Lenalidomide
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
705 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
78
States / cities
Birmingham, Alabama • Chandler, Arizona • Tucson, Arizona + 75 more
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effect of Sitagliptin on Short-Term Metabolic Dysregulation of Oral Glucocorticoid Therapy

NCT01488279
Conditions
Pre-diabetes, Impaired Fasting Glucose, Impaired Glucose Tolerance
Interventions
Dexamethasone 2.5 mg and Sitagliptin 100 mg, Dexamethasone 2.5 mg and placebo tablet
Drug
Lead sponsor
University of Vermont
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
South Burlington, Vermont
Conditions
PTSD
Interventions
Virtual reality exposure therapy, 0.5 mg DEX
Behavioral · Drug
Lead sponsor
Emory University
Other
Eligibility
21 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Arthritis, Gouty
Interventions
canakinumab, dexamethasone, placebo matching canakinumab, placebo matching dexamethasone
Biological · Drug · Other
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
Birmingham, Alabama • New Brunswick, New Jersey
Conditions
Coronavirus Disease 2019 (COVID-19) Pneumonia
Interventions
Lenzilumab, Standard of Care
Biological · Drug
Lead sponsor
Humanigen, Inc.
Industry
Eligibility
18 Years and older
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
18
States / cities
Phoenix, Arizona • Irvine, California • Los Angeles, California + 13 more
Conditions
Chemotherapy-induced Nausea and Vomiting
Interventions
Rolapitant, Granisetron, Dexamethasone, Placebo
Drug
Lead sponsor
Tesaro, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,369 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Waltham, Massachusetts
Conditions
Relapsed/Refractory Multiple Myeloma
Interventions
Venetoclax, Bortezomib, Dexamethasone, Placebo for venetoclax
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 99 Years
Enrollment
291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
4
States / cities
Aurora, Colorado • Durham, North Carolina • Canton, Ohio
Terminated Phase 1Phase 2 Interventional Results available

Study Testing Radium-223 Dichloride in Relapsed Multiple Myeloma

NCT02928029
Conditions
Multiple Myeloma
Interventions
Radium-223 dichloride (Xofigo, BAY88-8223), Placebo, Bortezomib, Dexamethasone
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
3
States / cities
Encinitas, California • Winston-Salem, North Carolina • Seattle, Washington
Conditions
Hemorrhoids, Fissure in Ano, Rectal Fistula, Anal Condyloma
Interventions
Gabapentin, Ketamine, Acetaminophen, Dexamethasone, Placebo
Drug
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
Burlington, Vermont • Colchester, Vermont
Conditions
Multiple Myeloma
Interventions
Radium-223 dichloride (Xofigo, BAY88-8223), Placebo, Bortezomib, Dexamethasone
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
10
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Encinitas, California + 7 more
Conditions
Pain, Postoperative
Interventions
NMDA active, Steroid active, NMDA placebo, Steroid placebo
Drug
Lead sponsor
Population Health Research Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Multiple Myeloma
Interventions
CC-5013, Dexamethasone
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
353 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
44
States / cities
Hoover, Alabama • Duarte, California • Los Angeles, California + 38 more
Conditions
Carcinoma, Non Small Cell Lung
Interventions
Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®), Placebo, Docetaxel (Taxotere®), Dexamethasone (pre- and post-medication for docetaxel)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
913 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Bridgewater, New Jersey
Conditions
Relapsed Multiple Myeloma, Refractory Multiple Myeloma
Interventions
Ixazomib, Lenalidomide, Dexamethasone, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
722 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
18
States / cities
Little Rock, Arkansas • Anaheim, California • Berkeley, California + 15 more
Conditions
Nausea and Vomiting, Chemotherapy-Induced
Interventions
Casopitant, Dexamethasone, Placebo, Ondansetron
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
710 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
23
States / cities
Hot Springs, Arkansas • Corona, California • Fountain Valley, California + 19 more
Conditions
Chemotherapy-induced Nausea and Vomiting
Interventions
Rolapitant, Granisetron, Dexamethasone, Placebo
Drug
Lead sponsor
Tesaro, Inc.
Industry
Eligibility
18 Years and older
Enrollment
555 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Waltham, Massachusetts
Conditions
Relapsed/Refractory Diffuse Large B-cell Lymphoma
Interventions
Selinexor (combination therapy), Placebo matching for Selinexor (combination therapy), Rituximab (combination therapy), Gemcitabine (combination therapy), Dexamethasone (combination therapy), Cisplatin (combination therapy), Selinexor (continuous therapy), Placebo matching for Selinexor (continuous therapy)
Drug
Lead sponsor
Karyopharm Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
8
States / cities
Chandler, Arizona • Tucson, Arizona • Cerritos, California + 4 more
Conditions
Multiple Myeloma
Interventions
Masitinib, Placebo, Bortezomib, Dexamethasone
Drug
Lead sponsor
AB Science
Industry
Eligibility
18 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
5
States / cities
Galesburg, Illinois • Bethesda, Maryland • Charlotte, North Carolina + 2 more
Conditions
Germ Cell Tumors
Interventions
Aprepitant, Placebo
Drug
Lead sponsor
Hoosier Cancer Research Network
Other
Eligibility
15 Years and older · Male only
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
6
States / cities
Indianapolis, Indiana • Muncie, Indiana • St Louis, Missouri + 3 more
Conditions
Multiple Myeloma
Interventions
Siltuximab, Bortezomib, Placebo, Dexamethasone
Biological · Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2019
U.S. locations
11
States / cities
Greenbrae, California • Los Angeles, California • Indianapolis, Indiana + 8 more
Completed Phase 3 Interventional Results available

Adaptive COVID-19 Treatment Trial 4 (ACTT-4)

NCT04640168
Conditions
COVID-19
Interventions
Baricitinib, Dexamethasone, Placebo, Remdesivir
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
1,010 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
61
States / cities
Birmingham, Alabama • Fresno, California • La Jolla, California + 50 more
Conditions
Chemotherapy-induced Nausea and Vomiting
Interventions
Rolapitant, Granisetron, dexamethasone, Placebo
Drug
Lead sponsor
Tesaro, Inc.
Industry
Eligibility
18 Years and older
Enrollment
532 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Waltham, Massachusetts